Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions. Tonix’s lead product candidate, TNX-102 SL*, is in development for posttraumatic stress disorder (PTSD), fibromyalgia, agitation in Alzheimer’s disease (AAD) and alcohol use disorder (AUD). TNX-102 SL is in Phase 3 development as a bedtime treatment for PTSD and fibromyalgia. The AAD program is Phase 2 ready and the development for AUD is in the pre-IND application stage. Tonix is also developing TNX-601 CR as a daytime treatment for PTSD, as well as for depression. It is Phase 2-ready for a depression study, ex-U.S, and is expected to be IND-ready in the U.S. this year. Finally, Tonix also has a robust pipeline of preclinical products as well as biodefense programs.
*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.